No Data
No Data
Sailong Pharmaceutical GroupLtd's (SZSE:002898) Promising Earnings May Rest On Soft Foundations
Sailong Pharmaceutical Unit's Omeprazole Gets API Listing Approval in China
Sailong Pharmaceutical Group (002898.SZ): Subsidiary obtained the approval notice for the market application of the chemical raw material drug Omeprazole Sodium.
Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently obtained the "Chemical Raw Materials Drug Market Application Approval Notice" for Omeprazole Sodium issued by the National Medical Products Administration. The main indications for Omeprazole Sodium formulation are duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome.
Cailong Pharmaceuticals: 2024 Semi-Annual Report Summary
Cailong Pharmaceuticals: Semi-Annual Report 2024
Sailong Pharmaceutical Group (002898.SZ): The net income in the first half of the year was 1.7647 million yuan, a year-on-year decrease of 40.93%.
On August 28, Gelonhui reported the 2024 interim report for sailong pharmaceutical group (002898.SZ), with operating revenue of 0.156 billion yuan, a year-on-year decrease of 0.46%; a net income attributable to the shareholders of the listed company of 1.7647 million yuan, a year-on-year decrease of 40.93%; a non-recurring net income attributable to the shareholders of the listed company of 1.3731 million yuan; and an earnings per share of 0.0100 yuan.
No Data